SCHEMBL475828

SCHEMBL475828

C#CCC(O)C[C]=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3196665 0.87
SCHEMBL6556969 0.84
SCHEMBL28850965 0.74
SCHEMBL28850967 0.74
SCHEMBL16820919 0.73
SCHEMBL16820705 0.73
SCHEMBL5395212 0.73
SCHEMBL5773265 0.71
SCHEMBL10314780 0.71
SCHEMBL10314775 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3929207-B1 PEPTIDE FTTFTVT FOR USE IN TREATING FIBROSIS UNIV TEXAS (US) 2024-07-17 EP claimed
EP-3929207-A1 INHIBITION OF PULMONARY FIBROSIS WITH NUTLIN-3A AND PEPTIDES Board of Regents, The University of Texas System (US) 2021-12-29 EP claimed
US-20180086791-A1 INHIBITION OF PULMONARY FIBROSIS WITH NUTLIN-3A AND PEPTIDES UNIV TEXAS (US) 2018-03-29 US claimed
EP-3929207-B1 PEPTIDE FTTFTVT FOR USE IN TREATING FIBROSIS UNIV TEXAS (US) 2024-07-17 EP disclosed
US-20240067713-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF CHRONIC LUNG DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2024-02-29 US disclosed
US-20240059736-A1 INHIBITION OF PULMONARY FIBROSIS WITH NUTLIN-3A AND PEPTIDES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2024-02-22 US disclosed
US-11905336-B2 Modified peptide fragments of CAV-1 protein and the use thereof in the treatment of fibrosis LUNG THERAPEUTICS, INC. (US) 2024-02-20 US disclosed
US-20240018186-A1 MODIFIED PEPTIDE FRAGMENTS OF CAV-1 PROTEIN AND THE USE THEREOF IN THE TREATMENT OF FIBROSIS LUNG THERAPEUTICS, INC. (US) 2024-01-18 US disclosed
WO-2024015857-A2 MODIFIED CAVEOLIN-1 PEPTIDE FORMULATIONS AND METHODS OF MANUFACTURING AND USE THEREOF LUNG THERAPEUTICS, INC. (US) 2024-01-18 WO disclosed
US-11787838-B2 Modified peptide fragments of CAV-1 protein and the use thereof in the treatment of fibrosis LUNG THERAPEUTICS, INC. (US) 2023-10-17 US disclosed
US-11780879-B2 Inhibition of pulmonary fibrosis with nutlin-3A and peptides BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-10-10 US disclosed
WO-2003012395-A2 EARLY DETECTION OF MYCOBACTERIAL DISEASE USING PEPTIDES NEW YORK UNIVERSITY (US) 2003-02-13 WO disclosed
US-20030027768-A1 Anti-invasive and anti-angiogenic compositions MAZAR ANDREW P (US) 2003-02-06 US disclosed
WO-2002069885-A2 ANTI-INVASIVE AND ANTI-ANGIOGENIC COMPOSITIONS AND METHODS FOR TREATING BRAIN TUMORS AND OTHER DISEASES ANGSTROM PHARMACEUTICALS, INC. (US) 2002-09-12 WO disclosed
WO-2002064621-A2 HISTIDINE PROLINE RICH GLYCOPROTEIN (HPRG) AS AN ANTI-ANGIOGENIC AND ANTI-TUMOR AGENT ATTENUON, LLC (US) 2002-08-22 WO disclosed
WO-2002014369-A2 HUMAN KININOGEN D5 DOMAIN POLYPEPTIDES AND THEIR USE ATTENUON, LLC (US) 2002-02-21 WO disclosed
WO-2001098343-A2 CONSERVED DIAPHANOUS-RELATED FORMIN AUTOREGULATORY DOMAIN (DAD) VAN ANDEL INSTITUTE (US) 2001-12-27 WO disclosed
US-5994309-A OCTAPEPTIDE; ANTITUMOR AGENT ANGSTROM PHARMACEUTICALS, INC. (US) 1999-11-30 US disclosed
EP-0950096-A1 ANTI-INVASIVE AND ANTI-ANGIOGENIC UROKINASE FRAGMENTS AND THEIR USE Angstrom Pharmaceuticals, inc. (US) 1999-10-20 EP disclosed
WO-1999005263-A1 ANTI-INVASIVE AND ANTI-ANGIOGENIC UROKINASE FRAGMENTS AND THEIR USE ANGSTROM PHARMACEUTICALS, INC. (US) 1999-02-04 WO disclosed